Sun's takeover of Ranbaxy may hurt competition: CCI

Tags: News
India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.

Sun and Ranbaxy have been asked by the regulator to publish details of the deal within 10 working days on their websites as well as in four national newspapers. The CCI also sought comments or objections from the public on the proposed deal.

Sun Pharma agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd to create the world's fifth-largest maker of generic drugs. Both companies have previously said they expect to complete the deal by December.

EDITORIAL OF THE DAY

  • India’s commercial links with Britain since Company Raj will still prosper

    There is little point in shedding tears over Britain’s exit from the European Union (EU).

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Amita Sharma

Regimenting art runs counter to a creative society

For poetry makes nothing happen,” so said American poet WH ...

Zehra Naqvi

Of traitors & cadavers

There’s nothing like a book that arrests you from the ...

Dharmendra Khandal

Why drone technology doesn't work

Poaching and anti-forestry activities are a problem for forest departments ...